secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001437749-24-003055
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex CFO to cover CEO during treatment; first patient dosed in Phase 2a expansion of Reqorsa
--------------------------------------------------------------------------------

- Catherine Vaczy, EVP and General Counsel, resigned effective Feb 4; company and Vaczy in discussions.
- CEO Rodney Varner undergoing treatment for cutaneous lymphoma; Board designates CFO Ryan Confer to act when CEO unavailable.
- First patient dosed Jan 2024 in Phase 2a expansion of Acclaim-1 study (Reqorsa + Tagrisso for NSCLC).
- Expects to complete Phase 2a enrollment (19 per cohort) by end of 2024; interim analysis in 2025.
- Phase 1 data showed no dose-limiting toxicities and extended progression-free survival in some patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774924003055/0001437749-24-003055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774924003055/gnpx20240204_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-003055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer